Tavneos

Overview

avacopan

complement inhibitor

• CYP3A4 substrate
• CYP3A4 inhibitor, moderate
• immunomodulatory effects

Contraindicated

• BCG live intravesical
Tavneos (avacopan)

+

BCG live intravesical

1 interaction

Contraindicated

avacopan + BCG live intravesical

contraindicated: combo may incr. risk of disseminated BCG infection; may decr. immune response (immunosuppressive effects)

• cisapride
Tavneos (avacopan)

+

cisapride

1 interaction

Contraindicated

avacopan + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• eliglustat
Tavneos (avacopan)

+

eliglustat

1 interaction

Contraindicated

avacopan + eliglustat

CYP2D6 EM: contraindicated if also combined w/ moderate or strong CYP2D6 inhibitor; otherwise, monitor ECG; decr. eliglustat dose to 84 mg qd; CYP2D6 IM: contraindicated if also combined w/ moderate or strong CYP2D6 inhibitor; otherwise, avoid combo; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• flibanserin
Tavneos (avacopan)

+

flibanserin

1 interaction

Contraindicated

avacopan + flibanserin

contraindicated w/in 14 days prior to, during, and x2 days after flibanserin tx: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), other adverse effects (hepatic metabolism inhibited)

• lomitapide
Tavneos (avacopan)

+

lomitapide

1 interaction

Contraindicated

avacopan + lomitapide

contraindicated: combo may incr. lomitapide levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

• talimogene laherparepvec
Tavneos (avacopan)

+

talimogene laherparepvec

1 interaction

Contraindicated

avacopan + talimogene laherparepvec

contraindicated: combo may incr. risk of disseminated herpetic infection; may decr. immune response (immunosuppressive effects)

Avoid/Use Alternative

• alfentanil
Tavneos (avacopan)

+

alfentanil

1 interaction

Avoid/Use Alternative

avacopan + alfentanil

use alternative or monitor respiratory rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and respiratory depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metabolism inhibited)

• alprazolam
Tavneos (avacopan)

+

alprazolam

1 interaction

Avoid/Use Alternative

avacopan + alprazolam

use alternative or monitor respiratory rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• amiodarone
Tavneos (avacopan)

+

amiodarone

1 interaction

Avoid/Use Alternative

avacopan + amiodarone

use alternative or monitor ECG: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• apalutamide
Tavneos (avacopan)

+

apalutamide

1 interaction

Avoid/Use Alternative

avacopan + apalutamide

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• aprepitant
Tavneos (avacopan)

+

aprepitant

1 interaction

Avoid/Use Alternative

avacopan + aprepitant

avoid combo w/ oral aprepitant; IV aprepitant use OK: combo may incr. levels of both drugs, risk of adverse effects (hepatic metabolism inhibited)

• avapritinib
Tavneos (avacopan)

+

avapritinib

1 interaction

Avoid/Use Alternative

avacopan + avapritinib

GIST: use alternative or monitor bleeding s/sx; decr. avapritinib start dose to 100 mg qd; ADVANCED SYSTEMIC MASTOCYTOSIS: use alternative or monitor bleeding s/sx; decr. avapritinib start dose to 50 mg qd; INDOLENT SYSTEMIC MASTOCYTOSIS: avoid combo: combo may incr. avapritinib levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• bosentan
Tavneos (avacopan)

+

bosentan

1 interaction

Avoid/Use Alternative

avacopan + bosentan

avoid combo: combo may incr. bosentan levels, risk of adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• bosutinib
Tavneos (avacopan)

+

bosutinib

1 interaction

Avoid/Use Alternative

avacopan + bosutinib

avoid combo: combo may incr. bosutinib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• brigatinib
Tavneos (avacopan)

+

brigatinib

1 interaction

Avoid/Use Alternative

avacopan + brigatinib

use alternative or monitor BP, HR; decr. brigatinib dose by approx. 40% as follows: if taking 180 mg, decr. to 120 mg, if taking 120 mg, decr. to 90 mg; if taking 90 mg, decr. to 60 mg: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• buspirone
Tavneos (avacopan)

+

buspirone

1 interaction

Avoid/Use Alternative

avacopan + buspirone

consider alternative or restart buspirone dose at 2.5 mg bid: combo may incr. buspirone levels, risk of adverse effects (hepatic metabolism inhibited)

• butalbital
Tavneos (avacopan)

+

butalbital

1 interaction

Avoid/Use Alternative

avacopan + butalbital

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• carbamazepine
Tavneos (avacopan)

+

carbamazepine

1 interaction

Avoid/Use Alternative

avacopan + carbamazepine

avoid combo: combo may decr. avacopan levels, efficacy; may incr. carbamazepine levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• cariprazine
Tavneos (avacopan)

+

cariprazine

1 interaction

Avoid/Use Alternative

avacopan + cariprazine

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING AVACOPAN: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• cenobamate
Tavneos (avacopan)

+

cenobamate

1 interaction

Avoid/Use Alternative

avacopan + cenobamate

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• cladribine oral
Tavneos (avacopan)

+

cladribine oral

1 interaction

Avoid/Use Alternative

avacopan + cladribine oral

use alternative: combo may incr. risk of serious infection (additive effects)

• cobimetinib
Tavneos (avacopan)

+

cobimetinib

1 interaction

Avoid/Use Alternative

avacopan + cobimetinib

avoid combo or decr. cobimetinib dose to 20 mg/day and D/C avacopan w/in 14 days: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metabolism inhibited)

• codeine
Tavneos (avacopan)

+

codeine

1 interaction

Avoid/Use Alternative

avacopan + codeine

use alternative or monitor respiratory rate, consider decr. codeine dose: combo may incr. codeine and active metabolite morphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, may incr. production of active metabolite morphine)

• colchicine
Tavneos (avacopan)

+

colchicine

1 interaction

Avoid/Use Alternative

avacopan + colchicine

CV RISK REDUCTION: avoid combo in pts w/ renal or hepatic impairment; otherwise, monitor CK, myopathy s/sx; GOUT or FMF: use alternative or decr. colchicine dose based on indication during and x14 days after avacopan use as follows: GOUT PROPHYLAXIS: give colchicine 0.3-0.6 mg/day divided qd-bid; ACUTE GOUT TX: avoid combo if already receiving colchicine for gout prophylaxis; otherwise, give colchicine 1.2 mg x1 only; FMF: decr. max colchicine dose to 1.2 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metabolism inhibited)

• conivaptan
Tavneos (avacopan)

+

conivaptan

1 interaction

Avoid/Use Alternative

avacopan + conivaptan

consider alternative: combo may incr. levels of both drugs, risk of overly rapid serum sodium correction, neurologic sequelae, other adverse effects (hepatic metabolism inhibited)

• dabrafenib
Tavneos (avacopan)

+

dabrafenib

1 interaction

Avoid/Use Alternative

avacopan + dabrafenib

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• defactinib
Tavneos (avacopan)

+

defactinib

1 interaction

Avoid/Use Alternative

avacopan + defactinib

avoid combo: combo may incr. defactinib levels, risk of adverse effects (hepatic metabolism inhibited)

• dihydrocodeine
Tavneos (avacopan)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

avacopan + dihydrocodeine

use alternative or monitor respiratory rate, consider decr. dihydrocodeine dose: combo may incr. dihydrocodeine and active metabolite dihydromorphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• dihydroergotamine
Tavneos (avacopan)

+

dihydroergotamine

1 interaction

Avoid/Use Alternative

avacopan + dihydroergotamine

use alternative: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• disopyramide
Tavneos (avacopan)

+

disopyramide

1 interaction

Avoid/Use Alternative

avacopan + disopyramide

use alternative or monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• domperidone
Tavneos (avacopan)

+

domperidone

1 interaction

Avoid/Use Alternative

avacopan + domperidone

avoid combo: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• dordaviprone
Tavneos (avacopan)

+

dordaviprone

1 interaction

Avoid/Use Alternative

avacopan + dordaviprone

use alternative or monitor ECG; for adult and pediatric pts weighing at least 52.5 kg, decr. dordaviprone dose to 500 mg once weekly; dose recommendation not established in pediatric pts weighing less than 52.5 kg: combo may incr. dordaviprone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• doxorubicin
Tavneos (avacopan)

+

doxorubicin

1 interaction

Avoid/Use Alternative

avacopan + doxorubicin

avoid combo: combo may incr. doxorubicin levels, risk serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

• efavirenz
Tavneos (avacopan)

+

efavirenz

1 interaction

Avoid/Use Alternative

avacopan + efavirenz

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• elacestrant
Tavneos (avacopan)

+

elacestrant

1 interaction

Avoid/Use Alternative

avacopan + elacestrant

avoid combo: combo may incr. elacestrant levels, risk of adverse effects (hepatic metabolism inhibited)

• encorafenib
Tavneos (avacopan)

+

encorafenib

1 interaction

Avoid/Use Alternative

avacopan + encorafenib

avoid combo: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• ensartinib
Tavneos (avacopan)

+

ensartinib

1 interaction

Avoid/Use Alternative

avacopan + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (hepatic metabolism possibly inhibited)

• entrectinib
Tavneos (avacopan)

+

entrectinib

1 interaction

Avoid/Use Alternative

avacopan + entrectinib

PEDS PTS w/ ENTRECTINIB START DOSE <200 mg/day: avoid combo; ADULT AND PEDS PTS >2yo: use alternative or monitor ECG, CBC, limit coadmin. to 14 days or less and decr. entrectinib dose as follows: if entrectinib start dose 200 mg qd, decr. to 50 mg qd; if entrectinib start dose 300 mg qd, decr. to 100 mg qd; if entrectinib start dose 400 or 600 mg qd, decr. to 200 mg qd: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• enzalutamide
Tavneos (avacopan)

+

enzalutamide

1 interaction

Avoid/Use Alternative

avacopan + enzalutamide

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• ergotamine
Tavneos (avacopan)

+

ergotamine

1 interaction

Avoid/Use Alternative

avacopan + ergotamine

use alternative: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• etrasimod
Tavneos (avacopan)

+

etrasimod

1 interaction

Avoid/Use Alternative

avacopan + etrasimod

avoid combo during and x5wk after etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects; infection risk may be prolonged (hepatic metabolism inhibited, additive effects)

• etravirine
Tavneos (avacopan)

+

etravirine

1 interaction

Avoid/Use Alternative

avacopan + etravirine

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• fentanyl
Tavneos (avacopan)

+

fentanyl

1 interaction

Avoid/Use Alternative

avacopan + fentanyl

use alternative or monitor respiratory rate, consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• fexinidazole
Tavneos (avacopan)

+

fexinidazole

1 interaction

Avoid/Use Alternative

avacopan + fexinidazole

avoid combo: combo may decr. avacopan levels, efficacy; may decr. fexinidazole active metabolite levels, efficacy (hepatic metabolism induced; hepatic metabolism inhibited, decr. conversion to active metabolites)

• fosaprepitant
Tavneos (avacopan)

+

fosaprepitant

1 interaction

Avoid/Use Alternative

avacopan + fosaprepitant

avoid combo: combo may incr. aprepitant levels, risk of adverse effects (hepatic metabolism inhibited)

• fosphenytoin
Tavneos (avacopan)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

avacopan + fosphenytoin

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• gepotidacin
Tavneos (avacopan)

+

gepotidacin

1 interaction

Avoid/Use Alternative

avacopan + gepotidacin

UROGENITAL GONORRHEA: use alternative or monitor ECG, electrolytes; URINARY TRACT INFECTION: consider monitoring ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• hydrocodone
Tavneos (avacopan)

+

hydrocodone

1 interaction

Avoid/Use Alternative

avacopan + hydrocodone

use alternative or monitor respiratory rate, ECG, consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ivabradine
Tavneos (avacopan)

+

ivabradine

1 interaction

Avoid/Use Alternative

avacopan + ivabradine

avoid combo: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ivacaftor
Tavneos (avacopan)

+

ivacaftor

1 interaction

Avoid/Use Alternative

avacopan + ivacaftor

pts <6 mo: avoid combo; pts >6 mo decr. ivacaftor dose as follows: 6 mo-5 yo and 5-6.9 kg: give 25 mg qd; 6 mo-5 yo and 7-13.9 kg: give 50 mg qd; 6 mo-5 yo and >14 kg: give 75 mg qd; 6 yo and older: give 150 mg qd: combo may incr. ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• ivosidenib
Tavneos (avacopan)

+

ivosidenib

1 interaction

Avoid/Use Alternative

avacopan + ivosidenib

avoid combo: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• ixabepilone
Tavneos (avacopan)

+

ixabepilone

1 interaction

Avoid/Use Alternative

avacopan + ixabepilone

consider alternatives or monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metabolism inhibited, additive effects)

• lemborexant
Tavneos (avacopan)

+

lemborexant

1 interaction

Avoid/Use Alternative

avacopan + lemborexant

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• levoketoconazole
Tavneos (avacopan)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

avacopan + levoketoconazole

consider alternative x2wk before and during levoketoconazole tx; otherwise, monitor ECG, decr. avacopan dose to 30 mg qd: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lonafarnib
Tavneos (avacopan)

+

lonafarnib

1 interaction

Avoid/Use Alternative

avacopan + lonafarnib

consider alternative or monitor HR, ECG, electrolytes, especially during first week when adding lonafarnib to existing avacopan tx; decr. avacopan dose to 30 mg qd: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lopinavir/ritonavir
Tavneos (avacopan)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

avacopan + lopinavir/ ritonavir

avoid combo: combo may alter avacopan levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

• lorlatinib
Tavneos (avacopan)

+

lorlatinib

1 interaction

Avoid/Use Alternative

avacopan + lorlatinib

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• lovastatin
Tavneos (avacopan)

+

lovastatin

1 interaction

Avoid/Use Alternative

avacopan + lovastatin

use alternative or monitor CK, myopathy sx; adjust lovastatin max dose to 20 mg/day: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• lumacaftor/ivacaftor
Tavneos (avacopan)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

avacopan + lumacaftor/ ivacaftor

avoid combo: combo may incr. ivacaftor levels, risk of adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• lurbinectedin
Tavneos (avacopan)

+

lurbinectedin

1 interaction

Avoid/Use Alternative

avacopan + lurbinectedin

use alternative or monitor CBC; decr. lurbinectedin dose 50%: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• macitentan
Tavneos (avacopan)

+

macitentan

1 interaction

Avoid/Use Alternative

avacopan + macitentan

if also combined w/ strong-mod CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. macitentan levels, risk of adverse effects (hepatic metabolism inhibited)

• mavacamten
Tavneos (avacopan)

+

mavacamten

1 interaction

Avoid/Use Alternative

avacopan + mavacamten

avoid combo: combo may incr. mavacamten levels, risk of heart failure, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• meperidine
Tavneos (avacopan)

+

meperidine

1 interaction

Avoid/Use Alternative

avacopan + meperidine

use alternative or monitor respiratory rate, ECG; consider decr. meperidine dose: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• methadone
Tavneos (avacopan)

+

methadone

1 interaction

Avoid/Use Alternative

avacopan + methadone

use alternative or monitor respiratory rate, ECG, consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• methylergonovine
Tavneos (avacopan)

+

methylergonovine

1 interaction

Avoid/Use Alternative

avacopan + methylergonovine

avoid combo: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• midazolam
Tavneos (avacopan)

+

midazolam

1 interaction

Avoid/Use Alternative

avacopan + midazolam

avoid combo if midazolam nasal use; otherwise, monitor respiratory rate, consider decr. midazolam dose: combo may incr. midazolam and active metabolite levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• mitapivat
Tavneos (avacopan)

+

mitapivat

1 interaction

Avoid/Use Alternative

avacopan + mitapivat

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• mitotane
Tavneos (avacopan)

+

mitotane

1 interaction

Avoid/Use Alternative

avacopan + mitotane

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• mobocertinib
Tavneos (avacopan)

+

mobocertinib

1 interaction

Avoid/Use Alternative

avacopan + mobocertinib

use alternative or monitor ECG; decr. mobocertinib dose as follows: if taking 160 mg, decr. dose to 80 mg; if taking 120 mg, decr. dose to 40 mg, if taking 80 mg, decr. dose to 40 mg: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• modafinil
Tavneos (avacopan)

+

modafinil

1 interaction

Avoid/Use Alternative

avacopan + modafinil

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• nafcillin
Tavneos (avacopan)

+

nafcillin

1 interaction

Avoid/Use Alternative

avacopan + nafcillin

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• naloxegol
Tavneos (avacopan)

+

naloxegol

1 interaction

Avoid/Use Alternative

avacopan + naloxegol

use alternative or decr. naloxegol dose to 12.5 mg/day: combo may incr. naloxegol levels, risk of adverse effects (hepatic metabolism inhibited)

• natalizumab
Tavneos (avacopan)

+

natalizumab

1 interaction

Avoid/Use Alternative

avacopan + natalizumab

avoid combo: combo may incr. risk of serious infection (additive effects)

• neratinib
Tavneos (avacopan)

+

neratinib

1 interaction

Avoid/Use Alternative

avacopan + neratinib

avoid combo if also combined w/ P-gp inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (hepatic metabolism inhibited)

• netupitant
Tavneos (avacopan)

+

netupitant

1 interaction

Avoid/Use Alternative

avacopan + netupitant

use alternative or consider decr. avacopan dose during and x1wk after (fos)netupitant tx: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• nirogacestat
Tavneos (avacopan)

+

nirogacestat

1 interaction

Avoid/Use Alternative

avacopan + nirogacestat

avoid combo: combo may incr. levels of both drugs, risk of hypophosphatemia, other adverse effects (hepatic metabolism inhibited)

• nisoldipine
Tavneos (avacopan)

+

nisoldipine

1 interaction

Avoid/Use Alternative

avacopan + nisoldipine

consider alternative or monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• olaparib
Tavneos (avacopan)

+

olaparib

1 interaction

Avoid/Use Alternative

avacopan + olaparib

use alternative or monitor CBC; decr. olaparib dose to 150 mg bid: combo may incr. olaparib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• oliceridine
Tavneos (avacopan)

+

oliceridine

1 interaction

Avoid/Use Alternative

avacopan + oliceridine

use alternative or monitor respiratory rate, ECG; consider decr. oliceridine frequency: combo may incr. oliceridine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• omaveloxolone
Tavneos (avacopan)

+

omaveloxolone

1 interaction

Avoid/Use Alternative

avacopan + omaveloxolone

use alternative or decr. omaveloxolone dose to 100 mg/day: combo may incr. omaveloxolone levels, risk of adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• oxycodone
Tavneos (avacopan)

+

oxycodone

1 interaction

Avoid/Use Alternative

avacopan + oxycodone

use alternative or monitor respiratory rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• pacritinib
Tavneos (avacopan)

+

pacritinib

1 interaction

Avoid/Use Alternative

avacopan + pacritinib

avoid combo: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (including life-threatening), other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• palovarotene
Tavneos (avacopan)

+

palovarotene

1 interaction

Avoid/Use Alternative

avacopan + palovarotene

use alternative or decr. palovarotene dose as follows: wt 10-19.9 kg maint. dose 1 mg daily, flare dose 5 mg daily wk 1-4, then 2.5 mg daily wk 5-12; wt 20-39.9 kg maint. dose 1.5 mg daily, flare dose 6 mg daily wk 1-4, then 3 mg daily wk 5-12; wt 40-59.9 kg maint. dose 2 mg daily, flare dose 7.5 mg daily wk 1-4, then 4 mg daily wk 5-12; wt 60 kg and greater or 14 yo and older maint. dose 2.5 mg daily, flare dose 10 mg daily wk 1-4, then 5 mg daily wk 5-12: combo may incr. palovarotene levels, risk of adverse effects (hepatic metabolism inhibited)

• pemigatinib
Tavneos (avacopan)

+

pemigatinib

1 interaction

Avoid/Use Alternative

avacopan + pemigatinib

use alternative or monitor phosphate and decr. pemigatinib dose as follows: if on pemigatinib 13.5 mg qd, decr. to 9 mg qd; if on pemigatinib 9 mg qd, decr. to 4.5 mg qd: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

• pentobarbital
Tavneos (avacopan)

+

pentobarbital

1 interaction

Avoid/Use Alternative

avacopan + pentobarbital

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• pexidartinib
Tavneos (avacopan)

+

pexidartinib

1 interaction

Avoid/Use Alternative

avacopan + pexidartinib

avoid combo: combo may decr. avacopan levels, efficacy; may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• phenobarbital
Tavneos (avacopan)

+

phenobarbital

1 interaction

Avoid/Use Alternative

avacopan + phenobarbital

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• phenytoin
Tavneos (avacopan)

+

phenytoin

1 interaction

Avoid/Use Alternative

avacopan + phenytoin

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• pimecrolimus topical
Tavneos (avacopan)

+

pimecrolimus topical

1 interaction

Avoid/Use Alternative

avacopan + pimecrolimus topical

avoid combo: combo may incr. risk of serious infection (additive effects)

• pimozide
Tavneos (avacopan)

+

pimozide

1 interaction

Avoid/Use Alternative

avacopan + pimozide

avoid combo: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• pralsetinib
Tavneos (avacopan)

+

pralsetinib

1 interaction

Avoid/Use Alternative

avacopan + pralsetinib

use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• primidone
Tavneos (avacopan)

+

primidone

1 interaction

Avoid/Use Alternative

avacopan + primidone

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• propafenone
Tavneos (avacopan)

+

propafenone

1 interaction

Avoid/Use Alternative

avacopan + propafenone

if CYP2D6 poor metabolizer or if also combined w/ CYP2D6 inhibitor, avoid combo; otherwise, monitor ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited)

• remibrutinib
Tavneos (avacopan)

+

remibrutinib

1 interaction

Avoid/Use Alternative

avacopan + remibrutinib

avoid combo: combo may incr. remibrutinib levels, risk of adverse effects (hepatic metabolism inhibited)

• repotrectinib
Tavneos (avacopan)

+

repotrectinib

1 interaction

Avoid/Use Alternative

avacopan + repotrectinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• rifabutin
Tavneos (avacopan)

+

rifabutin

1 interaction

Avoid/Use Alternative

avacopan + rifabutin

avoid combo: combo may incr. rifabutin levels, risk of myelosuppression, uveitis, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• rifampin
Tavneos (avacopan)

+

rifampin

1 interaction

Avoid/Use Alternative

avacopan + rifampin

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• rifapentine
Tavneos (avacopan)

+

rifapentine

1 interaction

Avoid/Use Alternative

avacopan + rifapentine

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• rilzabrutinib
Tavneos (avacopan)

+

rilzabrutinib

1 interaction

Avoid/Use Alternative

avacopan + rilzabrutinib

avoid combo if avacopan use greater than 7 days; use alternative or hold rilzabrutinib if avacopan use less than 7 days: combo may incr. levels of both drugs, risk of serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• rivaroxaban
Tavneos (avacopan)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

avacopan + rivaroxaban

use alternative if CrCl <80 and combined w/ P-gp inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (hepatic metabolism inhibited)

• selpercatinib
Tavneos (avacopan)

+

selpercatinib

1 interaction

Avoid/Use Alternative

avacopan + selpercatinib

use alternative or monitor ECG, electrolytes; decr. selpercatinib dose as follows: if on selpercatinib 40 mg tid, decr. to 40 mg qd; if on selpercatinib 80 mg bid, decr. to 40 mg bid; if on selpercatinib 120 mg bid, decr. to 80 mg bid; if on selpercatinib 160 mg bid, decr. to 120 mg bid: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• selumetinib
Tavneos (avacopan)

+

selumetinib

1 interaction

Avoid/Use Alternative

avacopan + selumetinib

use alternative or monitor LVEF, CK, myopathy sx; decr. selumetinib dose as follows: if on selumetinib 25 mg/m^2 bid, decr. to 20 mg/m^2 bid; if on selumetinib 20 mg/m^2 bid, decr. to 15 mg/m^2 bid; see selumetinib pkg insert for specific dose adjustments: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• simvastatin
Tavneos (avacopan)

+

simvastatin

1 interaction

Avoid/Use Alternative

avacopan + simvastatin

use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 10 mg/day; for pts previously tolerating 80 mg/day w/o muscle toxicity x12mo, adjust max simvastatin dose to 20 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• siponimod
Tavneos (avacopan)

+

siponimod

1 interaction

Avoid/Use Alternative

avacopan + siponimod

caution advised during and x3-4wk after siponimod tx; if also combined w/ strong CYP2C9 inhibitor, avoid combo; if also combined w/ moderate CYP2C9 inhibitor, monitor HR, ECG: combo may incr. siponimod levels, risk of PR interval prolongation, AV block, bradycardia, serious infection (infection risk may be prolonged), other adverse effects (hepatic metabolism inhibited, additive effects)

• sonidegib
Tavneos (avacopan)

+

sonidegib

1 interaction

Avoid/Use Alternative

avacopan + sonidegib

avoid combo or monitor closely: combo may incr. sonidegib levels, risk of adverse effects (hepatic metabolism inhibited)

• sotorasib
Tavneos (avacopan)

+

sotorasib

1 interaction

Avoid/Use Alternative

avacopan + sotorasib

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• St. John's wort
Tavneos (avacopan)

+

St. John's wort

1 interaction

Avoid/Use Alternative

avacopan + St. John's wort

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• sufentanil
Tavneos (avacopan)

+

sufentanil

1 interaction

Avoid/Use Alternative

avacopan + sufentanil

consider alternative or monitor respiratory rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• taletrectinib
Tavneos (avacopan)

+

taletrectinib

1 interaction

Avoid/Use Alternative

avacopan + taletrectinib

avoid combo: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• tazemetostat
Tavneos (avacopan)

+

tazemetostat

1 interaction

Avoid/Use Alternative

avacopan + tazemetostat

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• tolvaptan
Tavneos (avacopan)

+

tolvaptan

1 interaction

Avoid/Use Alternative

avacopan + tolvaptan

HYPONATREMIA USE: avoid combo; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DZ USE: decr. tolvaptan total daily dose by 50% as follows: if taking 60 mg/day, decr. to 15 mg qam and 15 mg qpm; if taking 90 mg/day, decr. to 30 mg qam and 15 mg qpm; if taking 120 mg/day, decr. to 45 mg qam and 15 mg qpm: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metabolism inhibited)

• tramadol
Tavneos (avacopan)

+

tramadol

1 interaction

Avoid/Use Alternative

avacopan + tramadol

use alternative or monitor respiratory rate, ECG, consider decr. tramadol dose: combo may incr. tramadol and active metabolite levels, risk of CNS and respiratory depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, may incr. production of active metabolite)

• vardenafil
Tavneos (avacopan)

+

vardenafil

1 interaction

Avoid/Use Alternative

avacopan + vardenafil

max vardenafil dose 5 mg/24h; avoid combo w/ ODT form; monitor ECG: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• venetoclax
Tavneos (avacopan)

+

venetoclax

1 interaction

Avoid/Use Alternative

avacopan + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, additive effects)

Monitor/Modify Tx

• abemaciclib
Tavneos (avacopan)

+

abemaciclib

1 interaction

Monitor/Modify Tx

avacopan + abemaciclib

consider decr. abemaciclib 200 mg bid dose to 150 mg bid, abemaciclib 150 mg bid dose to 100 mg bid, abemaciclib 100 mg bid dose to 50 mg bid; monitor CBC: combo may incr. abemaciclib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• acalabrutinib
Tavneos (avacopan)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

avacopan + acalabrutinib

decr. acalabrutinib dose to 100 mg qd; monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• adagrasib
Tavneos (avacopan)

+

adagrasib

1 interaction

Monitor/Modify Tx

avacopan + adagrasib

decr. avacopan dose to 30 mg qd; monitor ECG, electrolytes until adagrasib at steady state (approx. 8 days): combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• alfuzosin
Tavneos (avacopan)

+

alfuzosin

1 interaction

Monitor/Modify Tx

avacopan + alfuzosin

monitor BP, ECG: combo may incr. alfuzosin levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

• apixaban
Tavneos (avacopan)

+

apixaban

1 interaction

Monitor/Modify Tx

avacopan + apixaban

monitor bleeding s/sx, especially if also combined w/ P-gp inhibitor: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metabolism inhibited)

• aripiprazole oral
Tavneos (avacopan)

+

aripiprazole oral

1 interaction

Monitor/Modify Tx

avacopan + aripiprazole oral

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• artemether/lumefantrine
Tavneos (avacopan)

+

artemether/ lumefantrine

1 interaction

Monitor/Modify Tx

avacopan + artemether/ lumefantrine

monitor ECG: combo may incr. artemether/lumefantrine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• atazanavir
Tavneos (avacopan)

+

atazanavir

1 interaction

Monitor/Modify Tx

avacopan + atazanavir

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• atorvastatin
Tavneos (avacopan)

+

atorvastatin

1 interaction

Monitor/Modify Tx

avacopan + atorvastatin

monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• avanafil
Tavneos (avacopan)

+

avanafil

1 interaction

Monitor/Modify Tx

avacopan + avanafil

monitor BP; adjust max avanafil dose to 50 mg/24h: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• avatrombopag
Tavneos (avacopan)

+

avatrombopag

1 interaction

Monitor/Modify Tx

avacopan + avatrombopag

CHRONIC IMMUNE THROMBOCYTOPENIA: monitor platelets, thrombosis s/sx; if avatrombopag tablet also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 20 mg 3x/wk; if avatrombopag sprinkle also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 10 mg 3x/wk; CHRONIC LIVER DZ: monitor platelets, thrombosis s/sx: combo may incr. avatrombopag levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

• axitinib
Tavneos (avacopan)

+

axitinib

1 interaction

Monitor/Modify Tx

avacopan + axitinib

consider decr. axitinib dose: combo may incr. axitinib levels, risk of adverse effects (hepatic metabolism inhibited)

• brexpiprazole
Tavneos (avacopan)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

avacopan + brexpiprazole

if CYP2D6 poor metabolizer or if also combined w/ moderate or strong CYP2D6 inhibitor, decr. brexpiprazole dose 75%: combo may incr. brexpiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• bromocriptine
Tavneos (avacopan)

+

bromocriptine

1 interaction

Monitor/Modify Tx

avacopan + bromocriptine

limit bromocriptine max dose to 1.6 mg/day if diabetes tx; otherwise, caution advised: combo may incr. bromocriptine levels, risk of adverse effects (hepatic metabolism inhibited)

• budesonide
Tavneos (avacopan)

+

budesonide

1 interaction

Monitor/Modify Tx

avacopan + budesonide

monitor hypercorticism s/sx: combo may incr. budesonide levels, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• butorphanol
Tavneos (avacopan)

+

butorphanol

1 interaction

Monitor/Modify Tx

avacopan + butorphanol

monitor respiratory rate, consider decr. butorphanol dose: combo may incr. butorphanol levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• cabozantinib
Tavneos (avacopan)

+

cabozantinib

1 interaction

Monitor/Modify Tx

avacopan + cabozantinib

monitor ECG, BP, bleeding s/sx: combo may incr. cabozantinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• capivasertib
Tavneos (avacopan)

+

capivasertib

1 interaction

Monitor/Modify Tx

avacopan + capivasertib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• carfilzomib
Tavneos (avacopan)

+

carfilzomib

1 interaction

Monitor/Modify Tx

avacopan + carfilzomib

consider antiviral prophylaxis: combo may incr. risk of serious infection (additive effects)

• ceritinib
Tavneos (avacopan)

+

ceritinib

1 interaction

Monitor/Modify Tx

avacopan + ceritinib

monitor ECG, electrolytes; decr. avacopan dose to 30 mg qd: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• chloramphenicol
Tavneos (avacopan)

+

chloramphenicol

1 interaction

Monitor/Modify Tx

avacopan + chloramphenicol

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• cilostazol
Tavneos (avacopan)

+

cilostazol

1 interaction

Monitor/Modify Tx

avacopan + cilostazol

decr. cilostazol dose to 50 mg bid: combo may incr. cilostazol levels, risk of adverse effects (hepatic metabolism inhibited)

• clarithromycin
Tavneos (avacopan)

+

clarithromycin

1 interaction

Monitor/Modify Tx

avacopan + clarithromycin

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• clonazepam
Tavneos (avacopan)

+

clonazepam

1 interaction

Monitor/Modify Tx

avacopan + clonazepam

monitor respiratory rate: combo may incr. clonazepam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• clozapine
Tavneos (avacopan)

+

clozapine

1 interaction

Monitor/Modify Tx

avacopan + clozapine

monitor ECG, BP, HR; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, other adverse effects (hepatic metabolism inhibited)

• cobicistat
Tavneos (avacopan)

+

cobicistat

1 interaction

Monitor/Modify Tx

avacopan + cobicistat

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• copanlisib
Tavneos (avacopan)

+

copanlisib

1 interaction

Monitor/Modify Tx

avacopan + copanlisib

monitor CBC: combo may incr. copanlisib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• crizotinib
Tavneos (avacopan)

+

crizotinib

1 interaction

Monitor/Modify Tx

avacopan + crizotinib

monitor ECG, electrolytes: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• cyclosporine
Tavneos (avacopan)

+

cyclosporine

1 interaction

Monitor/Modify Tx

avacopan + cyclosporine

monitor cyclosporine levels, renal fxn: combo may incr. levels of both drugs, risk of serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

• daridorexant
Tavneos (avacopan)

+

daridorexant

1 interaction

Monitor/Modify Tx

avacopan + daridorexant

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• dasatinib
Tavneos (avacopan)

+

dasatinib

1 interaction

Monitor/Modify Tx

avacopan + dasatinib

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• deflazacort
Tavneos (avacopan)

+

deflazacort

1 interaction

Monitor/Modify Tx

avacopan + deflazacort

decr. deflazacort to 1/3 usual dose: combo may incr. deflazacort active metabolite levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection (hepatic metabolism inhibited, additive effects)

• docetaxel
Tavneos (avacopan)

+

docetaxel

1 interaction

Monitor/Modify Tx

avacopan + docetaxel

monitor CBC; consider decr. docetaxel dose: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• dofetilide
Tavneos (avacopan)

+

dofetilide

1 interaction

Monitor/Modify Tx

avacopan + dofetilide

monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• dronedarone
Tavneos (avacopan)

+

dronedarone

1 interaction

Monitor/Modify Tx

avacopan + dronedarone

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• elexacaftor/tezacaftor/ivacaftor
Tavneos (avacopan)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

avacopan + elexacaftor/ tezacaftor/ ivacaftor

2-5 YO: decr. usual morning dose by alternating between one elexacaftor/tezacaftor/ivacaftor packet (Day 1) and one ivacaftor packet (Day 2), no evening doses; 6 YO AND OLDER: decr. usual morning dose by alternating between two elexacaftor/tezacaftor/ivacaftor tablets (Day 1) and one ivacaftor tablet (Day 2), no evening doses: combo may incr. elexacaftor/tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• elinzanetant
Tavneos (avacopan)

+

elinzanetant

1 interaction

Monitor/Modify Tx

avacopan + elinzanetant

decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• eplerenone
Tavneos (avacopan)

+

eplerenone

1 interaction

Monitor/Modify Tx

avacopan + eplerenone

ALL INDICATIONS: monitor potassium, renal fxn; POST-MI HFrEF: adjust max eplerenone dose to 25 mg/day; HTN: start eplerenone 25 mg qd, adjust max eplerenone dose to 50 mg/day: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

• erdafitinib
Tavneos (avacopan)

+

erdafitinib

1 interaction

Monitor/Modify Tx

avacopan + erdafitinib

monitor phosphate: combo may incr. erdafitinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

• erythromycin
Tavneos (avacopan)

+

erythromycin

1 interaction

Monitor/Modify Tx

avacopan + erythromycin

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• estazolam
Tavneos (avacopan)

+

estazolam

1 interaction

Monitor/Modify Tx

avacopan + estazolam

monitor respiratory rate; consider decr. estazolam dose: combo may incr. estazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• estradiol (contraceptive)
Tavneos (avacopan)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

avacopan + estradiol (contraceptive)

monitor thrombosis s/sx: combo may incr. estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

• ethinyl estradiol (contraceptive)
Tavneos (avacopan)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

avacopan + ethinyl estradiol (contraceptive)

monitor thrombosis s/sx especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

• everolimus
Tavneos (avacopan)

+

everolimus

1 interaction

Monitor/Modify Tx

avacopan + everolimus

monitor CBC; consider admin. PCP prophylaxis; BREAST CA, PNET, RENAL CELL CA, or RENAL ANGIOMYOLIPOMA w/ TSC: if also combined w/ P-gp inhibitor, decr. everolimus to 2.5 mg/day, may incr. to 5 mg/day if tolerated; TSC-ASSOC. SEGA or TSC-ASSOC. PARTIAL-ONSET SEIZURES: if also combined w/ P-gp inhibitor, monitor everolimus levels and decr. everolimus 50%; give every other day if already on lowest available dose; otherwise, monitor everolimus levels; TRANSPLANT: monitor everolimus levels: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• fedratinib
Tavneos (avacopan)

+

fedratinib

1 interaction

Monitor/Modify Tx

avacopan + fedratinib

if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs; otherwise, caution advised: combo may incr. levels of both drugs, risk of myelosuppression, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

• felodipine
Tavneos (avacopan)

+

felodipine

1 interaction

Monitor/Modify Tx

avacopan + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metabolism inhibited)

• finerenone
Tavneos (avacopan)

+

finerenone

1 interaction

Monitor/Modify Tx

avacopan + finerenone

monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

• futibatinib
Tavneos (avacopan)

+

futibatinib

1 interaction

Monitor/Modify Tx

avacopan + futibatinib

monitor phosphate: combo may incr. futibatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

• gepirone
Tavneos (avacopan)

+

gepirone

1 interaction

Monitor/Modify Tx

avacopan + gepirone

monitor ECG, electrolytes; decr. gepirone dose 50%: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• gilteritinib
Tavneos (avacopan)

+

gilteritinib

1 interaction

Monitor/Modify Tx

avacopan + gilteritinib

monitor ECG: combo may incr. gilteritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• glasdegib
Tavneos (avacopan)

+

glasdegib

1 interaction

Monitor/Modify Tx

avacopan + glasdegib

monitor CBC, ECG: combo may incr. glasdegib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• guanfacine
Tavneos (avacopan)

+

guanfacine

1 interaction

Monitor/Modify Tx

avacopan + guanfacine

decr. guanfacine ER dose 50%, consider decr. dose for immed.-release form: combo may incr. guanfacine levels, risk of adverse effects (hepatic metabolism inhibited)

• hydrocortisone
Tavneos (avacopan)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

avacopan + hydrocortisone

consider decr. hydrocortisone dose: combo may incr. hydrocortisone levels, risk of serious infection, systemic corticosteroid effects, including Cushing syndrome and adrenal suppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• ibrutinib
Tavneos (avacopan)

+

ibrutinib

1 interaction

Monitor/Modify Tx

avacopan + ibrutinib

B-CELL MALIGNANCIES: decr. ibrutinib dose to 280 mg qd; CHRONIC GVHD: consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• idelalisib
Tavneos (avacopan)

+

idelalisib

1 interaction

Monitor/Modify Tx

avacopan + idelalisib

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• iloperidone
Tavneos (avacopan)

+

iloperidone

1 interaction

Monitor/Modify Tx

avacopan + iloperidone

monitor ECG: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• irinotecan
Tavneos (avacopan)

+

irinotecan

1 interaction

Monitor/Modify Tx

avacopan + irinotecan

monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (hepatic metabolism inhibited, additive effects)

• itraconazole
Tavneos (avacopan)

+

itraconazole

1 interaction

Monitor/Modify Tx

avacopan + itraconazole

decr. avacopan dose to 30 mg qd; consider decr. itraconazole dose: combo may incr. levels of both drugs, risk of adverse effects (hepatic metabolism inhibited)

• ketoconazole
Tavneos (avacopan)

+

ketoconazole

1 interaction

Monitor/Modify Tx

avacopan + ketoconazole

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• lapatinib
Tavneos (avacopan)

+

lapatinib

1 interaction

Monitor/Modify Tx

avacopan + lapatinib

monitor ECG; consider decr. lapatinib dose: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• larotrectinib
Tavneos (avacopan)

+

larotrectinib

1 interaction

Monitor/Modify Tx

avacopan + larotrectinib

caution advised: combo may incr. larotrectinib levels, risk of adverse effects (hepatic metabolism inhibited)

• lefamulin
Tavneos (avacopan)

+

lefamulin

1 interaction

Monitor/Modify Tx

avacopan + lefamulin

ORAL LEFAMULIN: monitor ECG; IV lefamulin use OK: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lidocaine
Tavneos (avacopan)

+

lidocaine

1 interaction

Monitor/Modify Tx

avacopan + lidocaine

monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher with continuous infusion or higher doses for local anesthesia (hepatic metabolism inhibited)

• lumateperone
Tavneos (avacopan)

+

lumateperone

1 interaction

Monitor/Modify Tx

avacopan + lumateperone

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lurasidone
Tavneos (avacopan)

+

lurasidone

1 interaction

Monitor/Modify Tx

avacopan + lurasidone

monitor ECG; decr. lurasidone start dose to 20 mg or decr. usual lurasidone dose 50%, max 80 mg/day: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• mavorixafor
Tavneos (avacopan)

+

mavorixafor

1 interaction

Monitor/Modify Tx

avacopan + mavorixafor

monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• mefloquine
Tavneos (avacopan)

+

mefloquine

1 interaction

Monitor/Modify Tx

avacopan + mefloquine

monitor ECG: combo may incr. mefloquine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• midostaurin
Tavneos (avacopan)

+

midostaurin

1 interaction

Monitor/Modify Tx

avacopan + midostaurin

monitor ECG, CBC: combo may incr. midostaurin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• mifepristone
Tavneos (avacopan)

+

mifepristone

1 interaction

Monitor/Modify Tx

avacopan + mifepristone

decr. avacopan dose to 30 mg qd during and x14 days after daily mifepristone use: combo may incr. levels of both drugs, risk of adverse effects (hepatic metabolism inhibited)

• milsaperidone
Tavneos (avacopan)

+

milsaperidone

1 interaction

Monitor/Modify Tx

avacopan + milsaperidone

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• mitomycin
Tavneos (avacopan)

+

mitomycin

1 interaction

Monitor/Modify Tx

avacopan + mitomycin

caution advised; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of serious infection (additive effects)

• nefazodone
Tavneos (avacopan)

+

nefazodone

1 interaction

Monitor/Modify Tx

avacopan + nefazodone

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• nelfinavir
Tavneos (avacopan)

+

nelfinavir

1 interaction

Monitor/Modify Tx

avacopan + nelfinavir

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• nifedipine
Tavneos (avacopan)

+

nifedipine

1 interaction

Monitor/Modify Tx

avacopan + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• nilotinib
Tavneos (avacopan)

+

nilotinib

1 interaction

Monitor/Modify Tx

avacopan + nilotinib

monitor ECG, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• nimodipine
Tavneos (avacopan)

+

nimodipine

1 interaction

Monitor/Modify Tx

avacopan + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• nortriptyline
Tavneos (avacopan)

+

nortriptyline

1 interaction

Monitor/Modify Tx

avacopan + nortriptyline

monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metabolism inhibited)

• palbociclib
Tavneos (avacopan)

+

palbociclib

1 interaction

Monitor/Modify Tx

avacopan + palbociclib

monitor CBC: combo may incr. palbociclib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• pazopanib
Tavneos (avacopan)

+

pazopanib

1 interaction

Monitor/Modify Tx

avacopan + pazopanib

monitor ECG: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• pimavanserin
Tavneos (avacopan)

+

pimavanserin

1 interaction

Monitor/Modify Tx

avacopan + pimavanserin

consider monitoring ECG: combo may incr. pimavanserin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• pirtobrutinib
Tavneos (avacopan)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

avacopan + pirtobrutinib

monitor CBC: combo may incr. pirtobrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• ponatinib
Tavneos (avacopan)

+

ponatinib

1 interaction

Monitor/Modify Tx

avacopan + ponatinib

monitor CBC: combo may incr. ponatinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• posaconazole
Tavneos (avacopan)

+

posaconazole

1 interaction

Monitor/Modify Tx

avacopan + posaconazole

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• quetiapine
Tavneos (avacopan)

+

quetiapine

1 interaction

Monitor/Modify Tx

avacopan + quetiapine

monitor ECG; consider decr. quetiapine dose: combo may incr. quetiapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• quinidine (antiarrhythmic)
Tavneos (avacopan)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

avacopan + quinidine (antiarrhythmic)

monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• quinidine (CYP2D6 inhibitor)
Tavneos (avacopan)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Monitor/Modify Tx

avacopan + quinidine (CYP2D6 inhibitor)

monitor ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• quinine
Tavneos (avacopan)

+

quinine

1 interaction

Monitor/Modify Tx

avacopan + quinine

monitor ECG: combo may incr. quinine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• quizartinib
Tavneos (avacopan)

+

quizartinib

1 interaction

Monitor/Modify Tx

avacopan + quizartinib

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• ranolazine
Tavneos (avacopan)

+

ranolazine

1 interaction

Monitor/Modify Tx

avacopan + ranolazine

adjust ranolazine max dose to 1000 mg/day: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• red yeast rice
Tavneos (avacopan)

+

red yeast rice

1 interaction

Monitor/Modify Tx

avacopan + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, red yeast rice contains varying amounts of lovastatin)

• repaglinide
Tavneos (avacopan)

+

repaglinide

1 interaction

Monitor/Modify Tx

avacopan + repaglinide

monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

• ribociclib
Tavneos (avacopan)

+

ribociclib

1 interaction

Monitor/Modify Tx

avacopan + ribociclib

monitor ECG, electrolytes, CBC; decr. avacopan dose to 30 mg qd: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• rimegepant
Tavneos (avacopan)

+

rimegepant

1 interaction

Monitor/Modify Tx

avacopan + rimegepant

separate rimegepant doses by at least 48h: combo may incr. rimegepant levels, risk of adverse effects (hepatic metabolism inhibited)

• riociguat
Tavneos (avacopan)

+

riociguat

1 interaction

Monitor/Modify Tx

avacopan + riociguat

monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (hepatic metabolism inhibited)

• ritonavir
Tavneos (avacopan)

+

ritonavir

1 interaction

Monitor/Modify Tx

avacopan + ritonavir

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• ruxolitinib
Tavneos (avacopan)

+

ruxolitinib

1 interaction

Monitor/Modify Tx

avacopan + ruxolitinib

monitor CBC: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• ruxolitinib topical
Tavneos (avacopan)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

avacopan + ruxolitinib topical

monitor CBC: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• saxagliptin
Tavneos (avacopan)

+

saxagliptin

1 interaction

Monitor/Modify Tx

avacopan + saxagliptin

monitor glucose: combo may incr. saxagliptin levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

• sebetralstat
Tavneos (avacopan)

+

sebetralstat

1 interaction

Monitor/Modify Tx

avacopan + sebetralstat

consider monitoring ECG; decr. sebetralstat dose to 300 mg, may give second 300 mg dose at least 3h after first dose if needed: combo may incr. sebetralstat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• sertraline
Tavneos (avacopan)

+

sertraline

1 interaction

Monitor/Modify Tx

avacopan + sertraline

monitor ECG: combo may incr. sertraline levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• sildenafil
Tavneos (avacopan)

+

sildenafil

1 interaction

Monitor/Modify Tx

avacopan + sildenafil

monitor BP: combo may incr. sildenafil levels, risk of hypotension (including syncope), priapism, other adverse effects (hepatic metabolism inhibited)

• sipuleucel-T
Tavneos (avacopan)

+

sipuleucel-T

1 interaction

Monitor/Modify Tx

avacopan + sipuleucel-T

consider decr. avacopan dose or D/C during leukapheresis and sipuleucel-T admin.: combo may decr. efficacy of sipuleucel-T; may incr. risk of adverse effects (antagonistic effects; additive effects)

• sirolimus
Tavneos (avacopan)

+

sirolimus

1 interaction

Monitor/Modify Tx

avacopan + sirolimus

monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• sirolimus albumin-bound
Tavneos (avacopan)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

avacopan + sirolimus albumin-bound

decr. sirolimus albumin-bound dose to 56 mg/m2; monitor CBC, bleeding s/sx: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• sparsentan
Tavneos (avacopan)

+

sparsentan

1 interaction

Monitor/Modify Tx

avacopan + sparsentan

monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

• sunitinib
Tavneos (avacopan)

+

sunitinib

1 interaction

Monitor/Modify Tx

avacopan + sunitinib

consider monitoring ECG, electrolytes: combo may incr. sunitinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• suvorexant
Tavneos (avacopan)

+

suvorexant

1 interaction

Monitor/Modify Tx

avacopan + suvorexant

decr. suvorexant dose to 5 mg, max 10 mg/day: combo may incr. suvorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• suzetrigine
Tavneos (avacopan)

+

suzetrigine

1 interaction

Monitor/Modify Tx

avacopan + suzetrigine

start suzetrigine 100 mg x1 at least 1h before or 2h after food, after 12h give 50 mg q12h x3 doses, then after 12h give 50mg q24h: combo may incr. suzetrigine and active metabolite levels, risk of adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• tacrolimus
Tavneos (avacopan)

+

tacrolimus

1 interaction

Monitor/Modify Tx

avacopan + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• tadalafil
Tavneos (avacopan)

+

tadalafil

1 interaction

Monitor/Modify Tx

avacopan + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• tamsulosin
Tavneos (avacopan)

+

tamsulosin

1 interaction

Monitor/Modify Tx

avacopan + tamsulosin

monitor BP, especially w/ tamsulosin dose >0.4 mg: combo may incr. tamsulosin levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

• temsirolimus
Tavneos (avacopan)

+

temsirolimus

1 interaction

Monitor/Modify Tx

avacopan + temsirolimus

monitor CBC; consider decr. temsirolimus dose: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• tezacaftor/ivacaftor
Tavneos (avacopan)

+

tezacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

avacopan + tezacaftor/ ivacaftor

decr. dose by alternating tezacaftor/ivacaftor tab and ivacaftor tab at morning dose, no evening doses: combo may incr. tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• tipranavir
Tavneos (avacopan)

+

tipranavir

1 interaction

Monitor/Modify Tx

avacopan + tipranavir

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• tofacitinib
Tavneos (avacopan)

+

tofacitinib

1 interaction

Monitor/Modify Tx

avacopan + tofacitinib

ALL USES: monitor CBC; if also combined w/ strong CYP2C19 inhibitor, adjust tofacitinib as follows: ADULT RHEUMATOID or PSORIATIC ARTHRITIS or ANKYLOSING SPONDYLITIS: decr. to 5 mg qd; ADULT ULCERATIVE COLITIS: decr. induction to 5 mg bid using tabs or 11 mg qd using XR tab for up to 16 wks, followed by 5 mg qd maintenance using tabs; do not use XR tabs for maintenance doses; PEDIATRIC PSORIATIC ARTHRITIS, POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: decr. usual bid dose to qd: combo may incr. tofacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• toremifene
Tavneos (avacopan)

+

toremifene

1 interaction

Monitor/Modify Tx

avacopan + toremifene

monitor ECG: combo may incr. toremifene levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• trabectedin
Tavneos (avacopan)

+

trabectedin

1 interaction

Monitor/Modify Tx

avacopan + trabectedin

monitor CBC, cardiac function (including LVEF), LFTs: combo may incr. trabectedin levels, risk of myelosuppression, cardiotoxicity, hepatotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

• trazodone
Tavneos (avacopan)

+

trazodone

1 interaction

Monitor/Modify Tx

avacopan + trazodone

monitor ECG, BP: combo may incr. trazodone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

• triazolam
Tavneos (avacopan)

+

triazolam

1 interaction

Monitor/Modify Tx

avacopan + triazolam

monitor respiratory rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• tucatinib
Tavneos (avacopan)

+

tucatinib

1 interaction

Monitor/Modify Tx

avacopan + tucatinib

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• ubrogepant
Tavneos (avacopan)

+

ubrogepant

1 interaction

Monitor/Modify Tx

avacopan + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 24h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metabolism inhibited)

• vanzacaftor/tezacaftor/deutivacaftor
Tavneos (avacopan)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Monitor/Modify Tx

avacopan + vanzacaftor/ tezacaftor/ deutivacaftor

6-11 YO AND WT <40 KG: decr. vanzacaftor/tezacaftor/deutivacaftor dose to two tablets (4 mg/20 mg/50 mg each) qod; 6-11 YO AND WT 40 KG AND ABOVE: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qod; 12 YO AND OLDER: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qod: combo may incr. vanzacaftor/tezacaftor/deutivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• vemurafenib
Tavneos (avacopan)

+

vemurafenib

1 interaction

Monitor/Modify Tx

avacopan + vemurafenib

monitor ECG: combo may incr. vemurafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• vinblastine
Tavneos (avacopan)

+

vinblastine

1 interaction

Monitor/Modify Tx

avacopan + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• vincristine
Tavneos (avacopan)

+

vincristine

1 interaction

Monitor/Modify Tx

avacopan + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited, additive effects)

• vinorelbine
Tavneos (avacopan)

+

vinorelbine

1 interaction

Monitor/Modify Tx

avacopan + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited, additive effects)

• voclosporin
Tavneos (avacopan)

+

voclosporin

1 interaction

Monitor/Modify Tx

avacopan + voclosporin

monitor ECG, renal fxn; decr. voclosporin morning dose to 15.8 mg and evening dose to 7.9 mg: combo may incr. voclosporin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

• voriconazole
Tavneos (avacopan)

+

voriconazole

1 interaction

Monitor/Modify Tx

avacopan + voriconazole

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• warfarin
Tavneos (avacopan)

+

warfarin

1 interaction

Monitor/Modify Tx

avacopan + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• zanubrutinib
Tavneos (avacopan)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

avacopan + zanubrutinib

decr. zanubrutinib dose to 80 mg bid; monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• ziftomenib
Tavneos (avacopan)

+

ziftomenib

1 interaction

Monitor/Modify Tx

avacopan + ziftomenib

monitor ECG: combo may incr. ziftomenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

Caution Advised

• abatacept
Tavneos (avacopan)

+

abatacept

1 interaction

Caution Advised

avacopan + abatacept

caution advised: combo may incr. risk of serious infection (additive effects)

• abrocitinib
Tavneos (avacopan)

+

abrocitinib

1 interaction

Caution Advised

avacopan + abrocitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• adalimumab
Tavneos (avacopan)

+

adalimumab

1 interaction

Caution Advised

avacopan + adalimumab

caution advised: combo may incr. risk of serious infection (additive effects)

• afamitresgene autoleucel
Tavneos (avacopan)

+

afamitresgene autoleucel

1 interaction

Caution Advised

avacopan + afamitresgene autoleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• aldesleukin
Tavneos (avacopan)

+

aldesleukin

1 interaction

Caution Advised

avacopan + aldesleukin

caution advised: combo may incr. risk of serious infection (additive effects)

• alemtuzumab
Tavneos (avacopan)

+

alemtuzumab

1 interaction

Caution Advised

avacopan + alemtuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• aliskiren
Tavneos (avacopan)

+

aliskiren

1 interaction

Caution Advised

avacopan + aliskiren

caution advised: combo may incr. aliskiren levels, risk of adverse effects (hepatic metabolism inhibited)

• anakinra
Tavneos (avacopan)

+

anakinra

1 interaction

Caution Advised

avacopan + anakinra

caution advised: combo may incr. risk of serious infection (additive effects)

• anifrolumab
Tavneos (avacopan)

+

anifrolumab

1 interaction

Caution Advised

avacopan + anifrolumab

caution advised: combo may incr. risk of serious infection (additive effects)

• anti-thymocyte globulin
Tavneos (avacopan)

+

anti-thymocyte globulin

1 interaction

Caution Advised

avacopan + anti-thymocyte globulin

caution advised: combo may incr. risk of serious infection (additive effects)

• armodafinil
Tavneos (avacopan)

+

armodafinil

1 interaction

Caution Advised

avacopan + armodafinil

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• atidarsagene autotemcel
Tavneos (avacopan)

+

atidarsagene autotemcel

1 interaction

Caution Advised

avacopan + atidarsagene autotemcel

caution advised: combo may incr. risk of serious infection (additive effects)

• axicabtagene ciloleucel
Tavneos (avacopan)

+

axicabtagene ciloleucel

1 interaction

Caution Advised

avacopan + axicabtagene ciloleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• azacitidine
Tavneos (avacopan)

+

azacitidine

1 interaction

Caution Advised

avacopan + azacitidine

caution advised: combo may incr. risk of serious infection (additive effects)

• azathioprine
Tavneos (avacopan)

+

azathioprine

1 interaction

Caution Advised

avacopan + azathioprine

caution advised: combo may incr. risk of serious infection (additive effects)

• baricitinib
Tavneos (avacopan)

+

baricitinib

1 interaction

Caution Advised

avacopan + baricitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• basiliximab
Tavneos (avacopan)

+

basiliximab

1 interaction

Caution Advised

avacopan + basiliximab

caution advised: combo may incr. risk of serious infection (additive effects)

• beclomethasone inhaled
Tavneos (avacopan)

+

beclomethasone inhaled

1 interaction

Caution Advised

avacopan + beclomethasone inhaled

caution advised: combo may incr. risk of serious infection (additive effects)

• beclomethasone nasal
Tavneos (avacopan)

+

beclomethasone nasal

1 interaction

Caution Advised

avacopan + beclomethasone nasal

caution advised: combo may incr. risk of serious infection (additive effects)

• belatacept
Tavneos (avacopan)

+

belatacept

1 interaction

Caution Advised

avacopan + belatacept

caution advised: combo may incr. risk of serious infection (additive effects)

• belimumab
Tavneos (avacopan)

+

belimumab

1 interaction

Caution Advised

avacopan + belimumab

caution advised: combo may incr. risk of serious infection (additive effects)

• belinostat
Tavneos (avacopan)

+

belinostat

1 interaction

Caution Advised

avacopan + belinostat

caution advised: combo may incr. risk of serious infection (additive effects)

• belzutifan
Tavneos (avacopan)

+

belzutifan

1 interaction

Caution Advised

avacopan + belzutifan

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• bendamustine
Tavneos (avacopan)

+

bendamustine

1 interaction

Caution Advised

avacopan + bendamustine

caution advised: combo may incr. risk of serious infection (additive effects)

• berotralstat
Tavneos (avacopan)

+

berotralstat

1 interaction

Caution Advised

avacopan + berotralstat

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• betamethasone
Tavneos (avacopan)

+

betamethasone

1 interaction

Caution Advised

avacopan + betamethasone

caution advised: combo may incr. risk of serious infection (additive effects)

• bexarotene
Tavneos (avacopan)

+

bexarotene

1 interaction

Caution Advised

avacopan + bexarotene

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• bimekizumab
Tavneos (avacopan)

+

bimekizumab

1 interaction

Caution Advised

avacopan + bimekizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• blinatumomab
Tavneos (avacopan)

+

blinatumomab

1 interaction

Caution Advised

avacopan + blinatumomab

caution advised: combo may incr. risk of serious infection (additive effects)

• bortezomib
Tavneos (avacopan)

+

bortezomib

1 interaction

Caution Advised

avacopan + bortezomib

caution advised: combo may incr. risk of serious infection (additive effects)

• brentuximab vedotin
Tavneos (avacopan)

+

brentuximab vedotin

1 interaction

Caution Advised

avacopan + brentuximab vedotin

caution advised: combo may incr. risk of serious infection (additive effects)

• brexucabtagene autoleucel
Tavneos (avacopan)

+

brexucabtagene autoleucel

1 interaction

Caution Advised

avacopan + brexucabtagene autoleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• brodalumab
Tavneos (avacopan)

+

brodalumab

1 interaction

Caution Advised

avacopan + brodalumab

caution advised: combo may incr. risk of serious infection (additive effects)

• budesonide inhaled
Tavneos (avacopan)

+

budesonide inhaled

1 interaction

Caution Advised

avacopan + budesonide inhaled

caution advised: combo may incr. risk of serious infection (additive effects)

• budesonide nasal
Tavneos (avacopan)

+

budesonide nasal

1 interaction

Caution Advised

avacopan + budesonide nasal

caution advised: combo may incr. risk of serious infection (additive effects)

• budesonide rectal
Tavneos (avacopan)

+

budesonide rectal

1 interaction

Caution Advised

avacopan + budesonide rectal

caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• busulfan
Tavneos (avacopan)

+

busulfan

1 interaction

Caution Advised

avacopan + busulfan

caution advised: combo may incr. risk of serious infection (additive effects)

• cabazitaxel
Tavneos (avacopan)

+

cabazitaxel

1 interaction

Caution Advised

avacopan + cabazitaxel

caution advised: combo may incr. risk of serious infection (additive effects)

• canakinumab
Tavneos (avacopan)

+

canakinumab

1 interaction

Caution Advised

avacopan + canakinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• carboplatin
Tavneos (avacopan)

+

carboplatin

1 interaction

Caution Advised

avacopan + carboplatin

caution advised: combo may incr. risk of serious infection (additive effects)

• carmustine
Tavneos (avacopan)

+

carmustine

1 interaction

Caution Advised

avacopan + carmustine

caution advised: combo may incr. risk of serious infection (additive effects)

• certolizumab pegol
Tavneos (avacopan)

+

certolizumab pegol

1 interaction

Caution Advised

avacopan + certolizumab pegol

caution advised: combo may incr. risk of serious infection (additive effects)

• chlorambucil
Tavneos (avacopan)

+

chlorambucil

1 interaction

Caution Advised

avacopan + chlorambucil

caution advised: combo may incr. risk of serious infection (additive effects)

• ciltacabtagene autoleucel
Tavneos (avacopan)

+

ciltacabtagene autoleucel

1 interaction

Caution Advised

avacopan + ciltacabtagene autoleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• ciprofloxacin
Tavneos (avacopan)

+

ciprofloxacin

1 interaction

Caution Advised

avacopan + ciprofloxacin

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• cisplatin
Tavneos (avacopan)

+

cisplatin

1 interaction

Caution Advised

avacopan + cisplatin

caution advised: combo may incr. risk of serious infection (additive effects)

• cladribine injection
Tavneos (avacopan)

+

cladribine injection

1 interaction

Caution Advised

avacopan + cladribine injection

caution advised: combo may incr. risk of serious infection (additive effects)

• clobazam
Tavneos (avacopan)

+

clobazam

1 interaction

Caution Advised

avacopan + clobazam

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• clobetasol ophthalmic
Tavneos (avacopan)

+

clobetasol ophthalmic

1 interaction

Caution Advised

avacopan + clobetasol ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• clofarabine
Tavneos (avacopan)

+

clofarabine

1 interaction

Caution Advised

avacopan + clofarabine

caution advised: combo may incr. risk of serious infection (additive effects)

• clofazimine
Tavneos (avacopan)

+

clofazimine

1 interaction

Caution Advised

avacopan + clofazimine

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• coccidioides immitis skin test antigen
Tavneos (avacopan)

+

coccidioides immitis skin test antigen

1 interaction

Caution Advised

avacopan + coccidioides immitis skin test antigen

caution advised: combo may interfere with test results (antagonistic effects)

• corticotropin
Tavneos (avacopan)

+

corticotropin

1 interaction

Caution Advised

avacopan + corticotropin

caution advised: combo may incr. risk of serious infection (additive effects)

• cortisone
Tavneos (avacopan)

+

cortisone

1 interaction

Caution Advised

avacopan + cortisone

caution advised: combo may incr. risk of serious infection (additive effects)

• crovalimab
Tavneos (avacopan)

+

crovalimab

1 interaction

Caution Advised

avacopan + crovalimab

caution advised: combo may incr. risk of serious infection (additive effects)

• cyclophosphamide
Tavneos (avacopan)

+

cyclophosphamide

1 interaction

Caution Advised

avacopan + cyclophosphamide

caution advised: combo may decr. cyclophosphamide active metabolite levels, efficacy; may incr. risk of serious infection (hepatic metabolism possibly inhibited, decr. conversion to active metabolite; additive effects)

• cytarabine
Tavneos (avacopan)

+

cytarabine

1 interaction

Caution Advised

avacopan + cytarabine

caution advised: combo may incr. risk of serious infection (additive effects)

• dactinomycin
Tavneos (avacopan)

+

dactinomycin

1 interaction

Caution Advised

avacopan + dactinomycin

caution advised: combo may incr. risk of serious infection (additive effects)

• danazol
Tavneos (avacopan)

+

danazol

1 interaction

Caution Advised

avacopan + danazol

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• danicopan
Tavneos (avacopan)

+

danicopan

1 interaction

Caution Advised

avacopan + danicopan

caution advised: combo may incr. risk of serious infection (additive effects)

• danshen
Tavneos (avacopan)

+

danshen

1 interaction

Caution Advised

avacopan + danshen

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• daratumumab
Tavneos (avacopan)

+

daratumumab

1 interaction

Caution Advised

avacopan + daratumumab

caution advised: combo may incr. risk of serious infection (additive effects)

• darifenacin
Tavneos (avacopan)

+

darifenacin

1 interaction

Caution Advised

avacopan + darifenacin

caution advised: combo may incr. darifenacin levels, risk of adverse effects (hepatic metabolism inhibited)

• darolutamide
Tavneos (avacopan)

+

darolutamide

1 interaction

Caution Advised

avacopan + darolutamide

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• darunavir
Tavneos (avacopan)

+

darunavir

1 interaction

Caution Advised

avacopan + darunavir

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• daunorubicin
Tavneos (avacopan)

+

daunorubicin

1 interaction

Caution Advised

avacopan + daunorubicin

caution advised: combo may incr. risk of serious infection (additive effects)

• decitabine
Tavneos (avacopan)

+

decitabine

1 interaction

Caution Advised

avacopan + decitabine

caution advised: combo may incr. risk of serious infection (additive effects)

• delgocitinib topical
Tavneos (avacopan)

+

delgocitinib topical

1 interaction

Caution Advised

avacopan + delgocitinib topical

caution advised: combo may incr. risk of serious infection (additive effects)

• deucravacitinib
Tavneos (avacopan)

+

deucravacitinib

1 interaction

Caution Advised

avacopan + deucravacitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• deuruxolitinib
Tavneos (avacopan)

+

deuruxolitinib

1 interaction

Caution Advised

avacopan + deuruxolitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• dexamethasone
Tavneos (avacopan)

+

dexamethasone

1 interaction

Caution Advised

avacopan + dexamethasone

caution advised: combo may incr. dexamethasone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• dexamethasone ophthalmic
Tavneos (avacopan)

+

dexamethasone ophthalmic

1 interaction

Caution Advised

avacopan + dexamethasone ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• dicloxacillin
Tavneos (avacopan)

+

dicloxacillin

1 interaction

Caution Advised

avacopan + dicloxacillin

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• difluprednate ophthalmic
Tavneos (avacopan)

+

difluprednate ophthalmic

1 interaction

Caution Advised

avacopan + difluprednate ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• diltiazem
Tavneos (avacopan)

+

diltiazem

1 interaction

Caution Advised

avacopan + diltiazem

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• dimethyl fumarate
Tavneos (avacopan)

+

dimethyl fumarate

1 interaction

Caution Advised

avacopan + dimethyl fumarate

caution advised: combo may incr. risk of serious infection (additive effects)

• dinutuximab
Tavneos (avacopan)

+

dinutuximab

1 interaction

Caution Advised

avacopan + dinutuximab

caution advised: combo may incr. risk of serious infection (additive effects)

• diroximel fumarate
Tavneos (avacopan)

+

diroximel fumarate

1 interaction

Caution Advised

avacopan + diroximel fumarate

caution advised: combo may incr. risk of serious infection (additive effects)

• dupilumab
Tavneos (avacopan)

+

dupilumab

1 interaction

Caution Advised

avacopan + dupilumab

caution advised: combo may incr. risk of serious infection (additive effects)

• duvelisib
Tavneos (avacopan)

+

duvelisib

1 interaction

Caution Advised

avacopan + duvelisib

caution advised: combo may incr. levels of both drugs, risk of serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• echinacea
Tavneos (avacopan)

+

echinacea

1 interaction

Caution Advised

avacopan + echinacea

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• eculizumab
Tavneos (avacopan)

+

eculizumab

1 interaction

Caution Advised

avacopan + eculizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• efgartigimod alfa
Tavneos (avacopan)

+

efgartigimod alfa

1 interaction

Caution Advised

avacopan + efgartigimod alfa

caution advised: combo may incr. risk of serious infection (additive effects)

• elafibranor
Tavneos (avacopan)

+

elafibranor

1 interaction

Caution Advised

avacopan + elafibranor

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• elagolix
Tavneos (avacopan)

+

elagolix

1 interaction

Caution Advised

avacopan + elagolix

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• eletriptan
Tavneos (avacopan)

+

eletriptan

1 interaction

Caution Advised

avacopan + eletriptan

caution advised: combo may incr. eletriptan levels, risk of adverse effects (hepatic metabolism inhibited)

• elivaldogene autotemcel
Tavneos (avacopan)

+

elivaldogene autotemcel

1 interaction

Caution Advised

avacopan + elivaldogene autotemcel

caution advised: combo may incr. risk of serious infection (additive effects)

• elotuzumab
Tavneos (avacopan)

+

elotuzumab

1 interaction

Caution Advised

avacopan + elotuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• elranatamab
Tavneos (avacopan)

+

elranatamab

1 interaction

Caution Advised

avacopan + elranatamab

caution advised: combo may incr. risk of serious infection (additive effects)

• emapalumab
Tavneos (avacopan)

+

emapalumab

1 interaction

Caution Advised

avacopan + emapalumab

caution advised: combo may incr. risk of serious infection (additive effects)

• enasidenib
Tavneos (avacopan)

+

enasidenib

1 interaction

Caution Advised

avacopan + enasidenib

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• epcoritamab
Tavneos (avacopan)

+

epcoritamab

1 interaction

Caution Advised

avacopan + epcoritamab

caution advised: combo may incr. risk of serious infection (additive effects)

• epirubicin
Tavneos (avacopan)

+

epirubicin

1 interaction

Caution Advised

avacopan + epirubicin

caution advised: combo may incr. risk of serious infection (additive effects)

• eribulin
Tavneos (avacopan)

+

eribulin

1 interaction

Caution Advised

avacopan + eribulin

caution advised: combo may incr. risk of serious infection (additive effects)

• erlotinib
Tavneos (avacopan)

+

erlotinib

1 interaction

Caution Advised

avacopan + erlotinib

caution advised: combo may incr. erlotinib levels, risk of adverse effects (hepatic metabolism inhibited)

• eslicarbazepine acetate
Tavneos (avacopan)

+

eslicarbazepine acetate

1 interaction

Caution Advised

avacopan + eslicarbazepine acetate

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• etanercept
Tavneos (avacopan)

+

etanercept

1 interaction

Caution Advised

avacopan + etanercept

caution advised: combo may incr. risk of serious infection (additive effects)

• etoposide
Tavneos (avacopan)

+

etoposide

1 interaction

Caution Advised

avacopan + etoposide

caution advised: combo may incr. risk of serious infection (additive effects)

• etuvetidigene autotemcel
Tavneos (avacopan)

+

etuvetidigene autotemcel

1 interaction

Caution Advised

avacopan + etuvetidigene autotemcel

caution advised: combo may incr. risk of serious infection (additive effects)

• felbamate
Tavneos (avacopan)

+

felbamate

1 interaction

Caution Advised

avacopan + felbamate

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• fingolimod
Tavneos (avacopan)

+

fingolimod

1 interaction

Caution Advised

avacopan + fingolimod

caution advised during and x2mo after fingolimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• floxuridine
Tavneos (avacopan)

+

floxuridine

1 interaction

Caution Advised

avacopan + floxuridine

caution advised: combo may incr. risk of serious infection (additive effects)

• fluconazole
Tavneos (avacopan)

+

fluconazole

1 interaction

Caution Advised

avacopan + fluconazole

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• fludarabine
Tavneos (avacopan)

+

fludarabine

1 interaction

Caution Advised

avacopan + fludarabine

caution advised: combo may incr. risk of serious infection (additive effects)

• fludrocortisone
Tavneos (avacopan)

+

fludrocortisone

1 interaction

Caution Advised

avacopan + fludrocortisone

caution advised: combo may incr. risk of serious infection (additive effects)

• flunisolide nasal
Tavneos (avacopan)

+

flunisolide nasal

1 interaction

Caution Advised

avacopan + flunisolide nasal

caution advised: combo may incr. risk of serious infection (additive effects)

• fluocinolone intravitreal
Tavneos (avacopan)

+

fluocinolone intravitreal

1 interaction

Caution Advised

avacopan + fluocinolone intravitreal

caution advised: combo may incr. risk of serious infection (additive effects)

• fluorometholone ophthalmic
Tavneos (avacopan)

+

fluorometholone ophthalmic

1 interaction

Caution Advised

avacopan + fluorometholone ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• fluticasone furoate
Tavneos (avacopan)

+

fluticasone furoate

1 interaction

Caution Advised

avacopan + fluticasone furoate

caution advised: combo may incr. risk of serious infection (additive effects)

• fluticasone propionate
Tavneos (avacopan)

+

fluticasone propionate

1 interaction

Caution Advised

avacopan + fluticasone propionate

caution advised: combo may incr. risk of serious infection (additive effects)

• fosamprenavir
Tavneos (avacopan)

+

fosamprenavir

1 interaction

Caution Advised

avacopan + fosamprenavir

caution advised: combo may alter avacopan levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

• fruquintinib
Tavneos (avacopan)

+

fruquintinib

1 interaction

Caution Advised

avacopan + fruquintinib

caution advised: combo may incr. risk of serious infection (additive effects)

• garlic
Tavneos (avacopan)

+

garlic

1 interaction

Caution Advised

avacopan + garlic

caution advised w/ supplemental garlic; dietary intake OK: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• gemtuzumab ozogamicin
Tavneos (avacopan)

+

gemtuzumab ozogamicin

1 interaction

Caution Advised

avacopan + gemtuzumab ozogamicin

caution advised: combo may incr. risk of serious infection (additive effects)

• ginkgo
Tavneos (avacopan)

+

ginkgo

1 interaction

Caution Advised

avacopan + ginkgo

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• ginseng, Asian
Tavneos (avacopan)

+

ginseng, Asian

1 interaction

Caution Advised

avacopan + ginseng, Asian

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• glofitamab
Tavneos (avacopan)

+

glofitamab

1 interaction

Caution Advised

avacopan + glofitamab

caution advised: combo may incr. risk of serious infection (additive effects)

• glycerol phenylbutyrate
Tavneos (avacopan)

+

glycerol phenylbutyrate

1 interaction

Caution Advised

avacopan + glycerol phenylbutyrate

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• golimumab
Tavneos (avacopan)

+

golimumab

1 interaction

Caution Advised

avacopan + golimumab

caution advised: combo may incr. risk of serious infection (additive effects)

• grapefruit
Tavneos (avacopan)

+

grapefruit

1 interaction

Caution Advised

avacopan + grapefruit

caution advised: combo may incr. avacopan levels, risk of adverse effects (GI metabolism inhibited)

• grazoprevir
Tavneos (avacopan)

+

grazoprevir

1 interaction

Caution Advised

avacopan + grazoprevir

caution advised: combo may incr. grazoprevir levels, risk of adverse effects (hepatic metabolism inhibited)

• griseofulvin
Tavneos (avacopan)

+

griseofulvin

1 interaction

Caution Advised

avacopan + griseofulvin

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• guselkumab
Tavneos (avacopan)

+

guselkumab

1 interaction

Caution Advised

avacopan + guselkumab

caution advised: combo may incr. risk of serious infection (additive effects)

• hydrocortisone ophthalmic
Tavneos (avacopan)

+

hydrocortisone ophthalmic

1 interaction

Caution Advised

avacopan + hydrocortisone ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• hydroxyurea
Tavneos (avacopan)

+

hydroxyurea

1 interaction

Caution Advised

avacopan + hydroxyurea

caution advised: combo may incr. risk of serious infection (additive effects)

• ibritumomab tiuxetan
Tavneos (avacopan)

+

ibritumomab tiuxetan

1 interaction

Caution Advised

avacopan + ibritumomab tiuxetan

caution advised: combo may incr. risk of serious infection (additive effects)

• icotrokinra
Tavneos (avacopan)

+

icotrokinra

1 interaction

Caution Advised

avacopan + icotrokinra

caution advised: combo may incr. risk of serious infection (additive effects)

• idarubicin
Tavneos (avacopan)

+

idarubicin

1 interaction

Caution Advised

avacopan + idarubicin

caution advised: combo may incr. risk of serious infection (additive effects)

• idecabtagene vicleucel
Tavneos (avacopan)

+

idecabtagene vicleucel

1 interaction

Caution Advised

avacopan + idecabtagene vicleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• ifosfamide
Tavneos (avacopan)

+

ifosfamide

1 interaction

Caution Advised

avacopan + ifosfamide

caution advised: combo may decr. ifosfamide active metabolite levels, efficacy; may incr. risk of serious infection (hepatic metabolism inhibited, decr. active metabolite formation; additive effects)

• imatinib
Tavneos (avacopan)

+

imatinib

1 interaction

Caution Advised

avacopan + imatinib

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• imlunestrant
Tavneos (avacopan)

+

imlunestrant

1 interaction

Caution Advised

avacopan + imlunestrant

caution advised: combo may incr. imlunestrant levels, risk of adverse effects (hepatic metabolism inhibited)

• inebilizumab
Tavneos (avacopan)

+

inebilizumab

1 interaction

Caution Advised

avacopan + inebilizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• infliximab
Tavneos (avacopan)

+

infliximab

1 interaction

Caution Advised

avacopan + infliximab

caution advised: combo may incr. risk of serious infection (additive effects)

• inotuzumab ozogamicin
Tavneos (avacopan)

+

inotuzumab ozogamicin

1 interaction

Caution Advised

avacopan + inotuzumab ozogamicin

caution advised: combo may incr. risk of serious infection (additive effects)

• iptacopan
Tavneos (avacopan)

+

iptacopan

1 interaction

Caution Advised

avacopan + iptacopan

caution advised: combo may incr. risk of serious infection (additive effects)

• isatuximab
Tavneos (avacopan)

+

isatuximab

1 interaction

Caution Advised

avacopan + isatuximab

caution advised: combo may incr. risk of serious infection (additive effects)

• isavuconazonium
Tavneos (avacopan)

+

isavuconazonium

1 interaction

Caution Advised

avacopan + isavuconazonium

caution advised: combo may incr. levels of both drugs, risk of adverse effects (hepatic metabolism inhibited)

• istradefylline
Tavneos (avacopan)

+

istradefylline

1 interaction

Caution Advised

avacopan + istradefylline

caution advised: combo may incr. istradefylline levels, risk of adverse effects (hepatic metabolism inhibited)

• ixekizumab
Tavneos (avacopan)

+

ixekizumab

1 interaction

Caution Advised

avacopan + ixekizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• lebrikizumab
Tavneos (avacopan)

+

lebrikizumab

1 interaction

Caution Advised

avacopan + lebrikizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• leflunomide
Tavneos (avacopan)

+

leflunomide

1 interaction

Caution Advised

avacopan + leflunomide

caution advised: combo may incr. risk of serious infection (additive effects)

• lenacapavir
Tavneos (avacopan)

+

lenacapavir

1 interaction

Caution Advised

avacopan + lenacapavir

caution advised during and x9mo after lenacapavir tx: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• lenalidomide
Tavneos (avacopan)

+

lenalidomide

1 interaction

Caution Advised

avacopan + lenalidomide

caution advised: combo may incr. risk of serious infection (additive effects)

• letermovir
Tavneos (avacopan)

+

letermovir

1 interaction

Caution Advised

avacopan + letermovir

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• lifileucel
Tavneos (avacopan)

+

lifileucel

1 interaction

Caution Advised

avacopan + lifileucel

caution advised: combo may incr. risk of serious infection (additive effects)

• linvoseltamab
Tavneos (avacopan)

+

linvoseltamab

1 interaction

Caution Advised

avacopan + linvoseltamab

caution advised: combo may incr. risk of serious infection (additive effects)

• lisocabtagene maraleucel
Tavneos (avacopan)

+

lisocabtagene maraleucel

1 interaction

Caution Advised

avacopan + lisocabtagene maraleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• lomustine
Tavneos (avacopan)

+

lomustine

1 interaction

Caution Advised

avacopan + lomustine

caution advised: combo may incr. risk of serious infection (additive effects)

• loncastuximab tesirine
Tavneos (avacopan)

+

loncastuximab tesirine

1 interaction

Caution Advised

avacopan + loncastuximab tesirine

caution advised: combo may incr. risk of serious infection (additive effects)

• loteprednol ophthalmic
Tavneos (avacopan)

+

loteprednol ophthalmic

1 interaction

Caution Advised

avacopan + loteprednol ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Tavneos (avacopan)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Caution Advised

avacopan + lymphocyte immune globulin, anti-thymocyte globulin

caution advised: combo may incr. risk of serious infection (additive effects)

• maraviroc
Tavneos (avacopan)

+

maraviroc

1 interaction

Caution Advised

avacopan + maraviroc

caution advised: combo may incr. maraviroc levels, risk of adverse effects (hepatic metabolism inhibited)

• melphalan
Tavneos (avacopan)

+

melphalan

1 interaction

Caution Advised

avacopan + melphalan

caution advised: combo may incr. risk of serious infection (additive effects)

• mercaptopurine
Tavneos (avacopan)

+

mercaptopurine

1 interaction

Caution Advised

avacopan + mercaptopurine

caution advised: combo may incr. risk of serious infection (additive effects)

• meropenem
Tavneos (avacopan)

+

meropenem

1 interaction

Caution Advised

avacopan + meropenem

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism possibly induced)

• methotrexate
Tavneos (avacopan)

+

methotrexate

1 interaction

Caution Advised

avacopan + methotrexate

caution advised: combo may incr. risk of serious infection (additive effects)

• methylprednisolone
Tavneos (avacopan)

+

methylprednisolone

1 interaction

Caution Advised

avacopan + methylprednisolone

caution advised: combo may incr. methylprednisolone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection (hepatic metabolism inhibited, additive effects)

• mirikizumab
Tavneos (avacopan)

+

mirikizumab

1 interaction

Caution Advised

avacopan + mirikizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• mitoxantrone
Tavneos (avacopan)

+

mitoxantrone

1 interaction

Caution Advised

avacopan + mitoxantrone

caution advised: combo may incr. risk of serious infection (additive effects)

• mogamulizumab
Tavneos (avacopan)

+

mogamulizumab

1 interaction

Caution Advised

avacopan + mogamulizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• momelotinib
Tavneos (avacopan)

+

momelotinib

1 interaction

Caution Advised

avacopan + momelotinib

caution advised: combo may incr. risk of serious infection (additive effects)

• mometasone implant
Tavneos (avacopan)

+

mometasone implant

1 interaction

Caution Advised

avacopan + mometasone implant

caution advised: combo may incr. risk of serious infection (additive effects)

• mometasone inhaled
Tavneos (avacopan)

+

mometasone inhaled

1 interaction

Caution Advised

avacopan + mometasone inhaled

caution advised: combo may incr. risk of serious infection (additive effects)

• mometasone nasal
Tavneos (avacopan)

+

mometasone nasal

1 interaction

Caution Advised

avacopan + mometasone nasal

caution advised: combo may incr. risk of serious infection (additive effects)

• monomethyl fumarate
Tavneos (avacopan)

+

monomethyl fumarate

1 interaction

Caution Advised

avacopan + monomethyl fumarate

caution advised: combo may incr. risk of serious infection (additive effects)

• mosunetuzumab
Tavneos (avacopan)

+

mosunetuzumab

1 interaction

Caution Advised

avacopan + mosunetuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• mycophenolate mofetil
Tavneos (avacopan)

+

mycophenolate mofetil

1 interaction

Caution Advised

avacopan + mycophenolate mofetil

caution advised: combo may incr. risk of serious infection (additive effects)

• mycophenolic acid
Tavneos (avacopan)

+

mycophenolic acid

1 interaction

Caution Advised

avacopan + mycophenolic acid

caution advised: combo may incr. risk of serious infection (additive effects)

• nadofaragene firadenovec intravesical
Tavneos (avacopan)

+

nadofaragene firadenovec intravesical

1 interaction

Caution Advised

avacopan + nadofaragene firadenovec intravesical

caution advised: combo may incr. risk of disseminated adenovirus infection (immunosuppressive effects)

• naldemedine
Tavneos (avacopan)

+

naldemedine

1 interaction

Caution Advised

avacopan + naldemedine

caution advised: combo may incr. naldemedine levels, risk of adverse effects (hepatic metabolism inhibited)

• narsoplimab
Tavneos (avacopan)

+

narsoplimab

1 interaction

Caution Advised

avacopan + narsoplimab

caution advised: combo may incr. risk of serious infection (additive effects)

• nelarabine
Tavneos (avacopan)

+

nelarabine

1 interaction

Caution Advised

avacopan + nelarabine

caution advised: combo may incr. risk of serious infection (additive effects)

• nevirapine
Tavneos (avacopan)

+

nevirapine

1 interaction

Caution Advised

avacopan + nevirapine

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• nipocalimab
Tavneos (avacopan)

+

nipocalimab

1 interaction

Caution Advised

avacopan + nipocalimab

caution advised: combo may incr. risk of serious infection (additive effects)

• obecabtagene autoleucel
Tavneos (avacopan)

+

obecabtagene autoleucel

1 interaction

Caution Advised

avacopan + obecabtagene autoleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• obinutuzumab
Tavneos (avacopan)

+

obinutuzumab

1 interaction

Caution Advised

avacopan + obinutuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• ocrelizumab
Tavneos (avacopan)

+

ocrelizumab

1 interaction

Caution Advised

avacopan + ocrelizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• odevixibat
Tavneos (avacopan)

+

odevixibat

1 interaction

Caution Advised

avacopan + odevixibat

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• ofatumumab
Tavneos (avacopan)

+

ofatumumab

1 interaction

Caution Advised

avacopan + ofatumumab

caution advised: combo may incr. risk of serious infection (additive effects)

• olutasidenib
Tavneos (avacopan)

+

olutasidenib

1 interaction

Caution Advised

avacopan + olutasidenib

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism possibly induced)

• ospemifene
Tavneos (avacopan)

+

ospemifene

1 interaction

Caution Advised

avacopan + ospemifene

caution advised: combo may incr. ospemifene levels, risk of adverse effects (hepatic metabolism inhibited)

• oxaliplatin
Tavneos (avacopan)

+

oxaliplatin

1 interaction

Caution Advised

avacopan + oxaliplatin

caution advised: combo may incr. risk of serious infection (additive effects)

• oxcarbazepine
Tavneos (avacopan)

+

oxcarbazepine

1 interaction

Caution Advised

avacopan + oxcarbazepine

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• ozanimod
Tavneos (avacopan)

+

ozanimod

1 interaction

Caution Advised

avacopan + ozanimod

caution advised during and x3mo after ozanimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• paclitaxel
Tavneos (avacopan)

+

paclitaxel

1 interaction

Caution Advised

avacopan + paclitaxel

caution advised: combo may incr. risk of serious infection (additive effects)

• pegcetacoplan
Tavneos (avacopan)

+

pegcetacoplan

1 interaction

Caution Advised

avacopan + pegcetacoplan

caution advised: combo may incr. risk of serious infection (additive effects)

• pentostatin
Tavneos (avacopan)

+

pentostatin

1 interaction

Caution Advised

avacopan + pentostatin

caution advised: combo may incr. risk of serious infection (additive effects)

• perampanel
Tavneos (avacopan)

+

perampanel

1 interaction

Caution Advised

avacopan + perampanel

caution advised if on perampanel 12 mg/day: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• pioglitazone
Tavneos (avacopan)

+

pioglitazone

1 interaction

Caution Advised

avacopan + pioglitazone

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• polatuzumab vedotin
Tavneos (avacopan)

+

polatuzumab vedotin

1 interaction

Caution Advised

avacopan + polatuzumab vedotin

caution advised: combo may incr. risk of serious infection (additive effects)

• pomalidomide
Tavneos (avacopan)

+

pomalidomide

1 interaction

Caution Advised

avacopan + pomalidomide

caution advised: combo may incr. risk of serious infection (additive effects)

• ponesimod
Tavneos (avacopan)

+

ponesimod

1 interaction

Caution Advised

avacopan + ponesimod

caution advised during and x1-2wk after ponesimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• pozelimab
Tavneos (avacopan)

+

pozelimab

1 interaction

Caution Advised

avacopan + pozelimab

caution advised: combo may incr. risk of serious infection (additive effects)

• prednisolone
Tavneos (avacopan)

+

prednisolone

1 interaction

Caution Advised

avacopan + prednisolone

caution advised: combo may incr. risk of serious infection (additive effects)

• prednisolone ophthalmic
Tavneos (avacopan)

+

prednisolone ophthalmic

1 interaction

Caution Advised

avacopan + prednisolone ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• prednisone
Tavneos (avacopan)

+

prednisone

1 interaction

Caution Advised

avacopan + prednisone

caution advised: combo may decr. avacopan levels, efficacy; may incr. risk of serious infection (hepatic metabolism induced; additive effects)

• procarbazine
Tavneos (avacopan)

+

procarbazine

1 interaction

Caution Advised

avacopan + procarbazine

caution advised: combo may incr. risk of serious infection (additive effects)

• ravulizumab
Tavneos (avacopan)

+

ravulizumab

1 interaction

Caution Advised

avacopan + ravulizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• regorafenib
Tavneos (avacopan)

+

regorafenib

1 interaction

Caution Advised

avacopan + regorafenib

caution advised: combo may incr. risk of serious infection (additive effects)

• rilonacept
Tavneos (avacopan)

+

rilonacept

1 interaction

Caution Advised

avacopan + rilonacept

caution advised: combo may incr. risk of serious infection (additive effects)

• risankizumab
Tavneos (avacopan)

+

risankizumab

1 interaction

Caution Advised

avacopan + risankizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• ritlecitinib
Tavneos (avacopan)

+

ritlecitinib

1 interaction

Caution Advised

avacopan + ritlecitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• rituximab
Tavneos (avacopan)

+

rituximab

1 interaction

Caution Advised

avacopan + rituximab

caution advised: combo may incr. risk of serious infection (additive effects)

• roflumilast
Tavneos (avacopan)

+

roflumilast

1 interaction

Caution Advised

avacopan + roflumilast

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

• roflumilast topical
Tavneos (avacopan)

+

roflumilast topical

1 interaction

Caution Advised

avacopan + roflumilast topical

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

• romidepsin
Tavneos (avacopan)

+

romidepsin

1 interaction

Caution Advised

avacopan + romidepsin

caution advised: combo may incr. risk of serious infection (additive effects)

• ropeginterferon alfa-2b
Tavneos (avacopan)

+

ropeginterferon alfa-2b

1 interaction

Caution Advised

avacopan + ropeginterferon alfa-2b

caution advised: combo may incr. risk of serious infection (additive effects)

• rozanolixizumab
Tavneos (avacopan)

+

rozanolixizumab

1 interaction

Caution Advised

avacopan + rozanolixizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• rufinamide
Tavneos (avacopan)

+

rufinamide

1 interaction

Caution Advised

avacopan + rufinamide

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• sarilumab
Tavneos (avacopan)

+

sarilumab

1 interaction

Caution Advised

avacopan + sarilumab

caution advised: combo may decr. avacopan levels, efficacy; may incr. risk of serious infection (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C; additive effects)

• satralizumab
Tavneos (avacopan)

+

satralizumab

1 interaction

Caution Advised

avacopan + satralizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• secukinumab
Tavneos (avacopan)

+

secukinumab

1 interaction

Caution Advised

avacopan + secukinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• seladelpar
Tavneos (avacopan)

+

seladelpar

1 interaction

Caution Advised

avacopan + seladelpar

caution advised if CYP2C9 poor metabolizer or if also combined w/ moderate CYP2C9 inhibitor: combo may incr. seladelpar levels, risk of adverse effects (hepatic metabolism inhibited)

• selinexor
Tavneos (avacopan)

+

selinexor

1 interaction

Caution Advised

avacopan + selinexor

caution advised: combo may incr. risk of serious infection (additive effects)

• sevabertinib
Tavneos (avacopan)

+

sevabertinib

1 interaction

Caution Advised

avacopan + sevabertinib

caution advised: combo may incr. sevabertinib levels, risk of adverse effects (hepatic metabolism inhibited)

• sibeprenlimab
Tavneos (avacopan)

+

sibeprenlimab

1 interaction

Caution Advised

avacopan + sibeprenlimab

caution advised: combo may incr. risk of serious infection (additive effects)

• silodosin
Tavneos (avacopan)

+

silodosin

1 interaction

Caution Advised

avacopan + silodosin

caution advised: combo may incr. silodosin levels, risk of adverse effects (hepatic metabolism inhibited)

• siltuximab
Tavneos (avacopan)

+

siltuximab

1 interaction

Caution Advised

avacopan + siltuximab

caution advised: combo may incr. risk of serious infection (additive effects)

• sirolimus topical
Tavneos (avacopan)

+

sirolimus topical

1 interaction

Caution Advised

avacopan + sirolimus topical

caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metabolism inhibited)

• spesolimab
Tavneos (avacopan)

+

spesolimab

1 interaction

Caution Advised

avacopan + spesolimab

caution advised: combo may incr. risk of serious infection (additive effects)

• stiripentol
Tavneos (avacopan)

+

stiripentol

1 interaction

Caution Advised

avacopan + stiripentol

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism possibly induced)

• sulfasalazine
Tavneos (avacopan)

+

sulfasalazine

1 interaction

Caution Advised

avacopan + sulfasalazine

caution advised: combo may incr. risk of serious infection (additive effects)

• sunvozertinib
Tavneos (avacopan)

+

sunvozertinib

1 interaction

Caution Advised

avacopan + sunvozertinib

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• sutimlimab
Tavneos (avacopan)

+

sutimlimab

1 interaction

Caution Advised

avacopan + sutimlimab

caution advised: combo may incr. risk of serious infection (additive effects)

• tafasitamab
Tavneos (avacopan)

+

tafasitamab

1 interaction

Caution Advised

avacopan + tafasitamab

caution advised: combo may incr. risk of serious infection (additive effects)

• talquetamab
Tavneos (avacopan)

+

talquetamab

1 interaction

Caution Advised

avacopan + talquetamab

caution advised: combo may incr. risk of serious infection (additive effects)

• tarlatamab
Tavneos (avacopan)

+

tarlatamab

1 interaction

Caution Advised

avacopan + tarlatamab

caution advised: combo may incr. risk of serious infection (additive effects)

• teclistamab
Tavneos (avacopan)

+

teclistamab

1 interaction

Caution Advised

avacopan + teclistamab

caution advised: combo may incr. risk of serious infection (additive effects)

• tecovirimat
Tavneos (avacopan)

+

tecovirimat

1 interaction

Caution Advised

avacopan + tecovirimat

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• telotristat ethyl
Tavneos (avacopan)

+

telotristat ethyl

1 interaction

Caution Advised

avacopan + telotristat ethyl

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• temozolomide
Tavneos (avacopan)

+

temozolomide

1 interaction

Caution Advised

avacopan + temozolomide

caution advised: combo may incr. risk of serious infection (additive effects)

• teplizumab
Tavneos (avacopan)

+

teplizumab

1 interaction

Caution Advised

avacopan + teplizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• teriflunomide
Tavneos (avacopan)

+

teriflunomide

1 interaction

Caution Advised

avacopan + teriflunomide

caution advised: combo may incr. risk of serious infection (additive effects)

• thioguanine
Tavneos (avacopan)

+

thioguanine

1 interaction

Caution Advised

avacopan + thioguanine

caution advised: combo may incr. risk of serious infection (additive effects)

• thiotepa
Tavneos (avacopan)

+

thiotepa

1 interaction

Caution Advised

avacopan + thiotepa

caution advised: combo may incr. risk of serious infection (additive effects)

• ticagrelor
Tavneos (avacopan)

+

ticagrelor

1 interaction

Caution Advised

avacopan + ticagrelor

caution advised: combo may incr. ticagrelor levels, risk of dyspnea, bleeding, other adverse effects (hepatic metabolism inhibited)

• tildrakizumab
Tavneos (avacopan)

+

tildrakizumab

1 interaction

Caution Advised

avacopan + tildrakizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• tisagenlecleucel
Tavneos (avacopan)

+

tisagenlecleucel

1 interaction

Caution Advised

avacopan + tisagenlecleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• tocilizumab
Tavneos (avacopan)

+

tocilizumab

1 interaction

Caution Advised

avacopan + tocilizumab

caution advised: combo may decr. avacopan levels, efficacy; may incr. risk of serious infection (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes; additive effects)

• topiramate
Tavneos (avacopan)

+

topiramate

1 interaction

Caution Advised

avacopan + topiramate

caution advised especially w/ topiramate doses >200 mg/day: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• topotecan
Tavneos (avacopan)

+

topotecan

1 interaction

Caution Advised

avacopan + topotecan

caution advised: combo may incr. risk of serious infection (additive effects)

• tovorafenib
Tavneos (avacopan)

+

tovorafenib

1 interaction

Caution Advised

avacopan + tovorafenib

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• tralokinumab
Tavneos (avacopan)

+

tralokinumab

1 interaction

Caution Advised

avacopan + tralokinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• tretinoin
Tavneos (avacopan)

+

tretinoin

1 interaction

Caution Advised

avacopan + tretinoin

caution advised: combo may incr. tretinoin levels, risk of adverse effects (hepatic metabolism inhibited)

• triamcinolone
Tavneos (avacopan)

+

triamcinolone

1 interaction

Caution Advised

avacopan + triamcinolone

caution advised: combo may incr. risk of serious infection (additive effects)

• tuberculin purified protein derivative
Tavneos (avacopan)

+

tuberculin purified protein derivative

1 interaction

Caution Advised

avacopan + tuberculin purified protein derivative

caution advised during and x5-6wk after avacopan tx: combo may interfere with test results (antagonistic effects)

• ublituximab
Tavneos (avacopan)

+

ublituximab

1 interaction

Caution Advised

avacopan + ublituximab

caution advised: combo may incr. risk of serious infection (additive effects)

• upadacitinib
Tavneos (avacopan)

+

upadacitinib

1 interaction

Caution Advised

avacopan + upadacitinib

caution advised: combo may incr. upadacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• ustekinumab
Tavneos (avacopan)

+

ustekinumab

1 interaction

Caution Advised

avacopan + ustekinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• vaborbactam
Tavneos (avacopan)

+

vaborbactam

1 interaction

Caution Advised

avacopan + vaborbactam

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism possibly induced)

• vamorolone
Tavneos (avacopan)

+

vamorolone

1 interaction

Caution Advised

avacopan + vamorolone

caution advised: combo may decr. avacopan levels, efficacy; may incr. risk of serious infection (hepatic metabolism possibly induced; additive effects)

• vedolizumab
Tavneos (avacopan)

+

vedolizumab

1 interaction

Caution Advised

avacopan + vedolizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• verapamil
Tavneos (avacopan)

+

verapamil

1 interaction

Caution Advised

avacopan + verapamil

caution advised: combo may incr. levels of both drugs, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)

• vilazodone
Tavneos (avacopan)

+

vilazodone

1 interaction

Caution Advised

avacopan + vilazodone

caution advised: combo may incr. vilazodone levels, risk of adverse effects (hepatic metabolism inhibited)

• vilobelimab
Tavneos (avacopan)

+

vilobelimab

1 interaction

Caution Advised

avacopan + vilobelimab

caution advised: combo may incr. risk of serious infection (additive effects)

• vorasidenib
Tavneos (avacopan)

+

vorasidenib

1 interaction

Caution Advised

avacopan + vorasidenib

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism possibly induced)

• zilucoplan
Tavneos (avacopan)

+

zilucoplan

1 interaction

Caution Advised

avacopan + zilucoplan

caution advised: combo may incr. risk of serious infection (additive effects)